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Inherited epidermolysis bullosa (EB) is a rare group of 
genetically heterogeneous diseases, characterized by 
deficiencies in the adhesion of the connective tissue to 
the epithelium. Junctional EB and dystrophic EB, are the 
most severe types. Common clinical manifestations are 
mechanical fragility of the skin and mucosae, with blister 
formation and abnormal wound healing, the severity of 
the lesions depending on the distinct type (1–3). The 
oral cavity is frequently involved, but, although bullae 
and erosions are common, there is only one published 
study of therapy, reporting that sucralfate suspension 
can reduce the development and duration of blisters and 
ulcers, reduce the associated pain, and improve indices 
of gingival inflammation (4).
Autologous and allogeneic platelet (PLT) preparations, 
in particular a blood component termed “platelet gel”, 
traditionally obtained from adult blood platelets, are rich 
in regenerative growth factors, which are valu able for 
the treatment of chronic wounds (5). Recent findings on 
multiple biological properties of human umbilical cord 
blood (CB), and its high level of viral safety, prompted 
one group to produce PLT gel from CB (cord blood plate-
let gel; CBPG) (6), and another to detail its effectiveness 
for the treatment of EB skin lesions (7).
Low-level laser therapy (LLLT) has potential biosti-
mulating effects, improving wound healing, and is a 
possible treatment for autoimmune oral erosive lesions, 
with a notable analgesic effect (8).
We therefore performed a pilot evaluation of the effi-
cacy and safety of CBPG with LLLT for the treatment of 
inherited EB oral mucosal lesions, over a 3-day treatment 
period (one application each day).
PATIENTS AND METHODS
Patients with dystrophic EB and symptomatic oral lesions were 
prospectively selected between June and October 2015. The ethics 
review board of the “Azienda Ospedaliera Città della Salute e della 
Scienza of Turin”, Turin, Italy, approved the study (protocol num-
ber 0089210_CS/585/09-2015). Participants with long-standing 
ulcerations were selected.
CB units not fulfilling the criteria for banking for transplant 
purposes were processed within 48 h of collection to obtain CBPG 
according to the “Italian Cord Blood Platelet Gel project” protocol 
(9) (for complete details see Appendix S11).
Morphological changes were measured with a 15-mm periodon-
tal probe (PCPUNC15: Hu-Friedy®, Chicago, IL, USA).
The symptom score (for reporting pain) was recorded using a 
visual analogue scale (VAS); patients were requested to mark the 
scale at each visit, before and after the laser session.
The primary outcome measures were lesions’ size and pain; 
secondary outcome measure was adverse effects. All data were 
collected during a 6-month follow-up period (at 1 (T4), 4 (T5), 12 
(T6) and 24 (T7) weeks after the end of the therapy).
Wilcoxon’s signed rank was used to calculate the differences 
of the outcome data. p-values ≤ 0.05 were considered statistically 
significant. SPSS for Windows (version 11, SPSS Inc., Chicago, 
IL, USA) statistical software was utilized.
RESULTS
Seven patients (4 males) with dystrophic EB were in-
cluded. The mean age at baseline was 19.8 years (range 
8–34). Nineteen oral lesions were treated; the buccal 
mucosa was the most common site (37%) (Fig. 1), fol-
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Fig. 1. Oral lesions in dystrophic epidermolysis bullosa. Case 3: A right buccal mucosal lesion at (a) T1_day1, (b) T2_day2, (c) T3_day3, (d) 
T4_day7, and (e) T7_24 weeks after end of therapy.
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2512
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lowed by the lips (27%), tongue (21%), floor of the mouth 
(11%) and gingiva (4%). 
A statistically significant difference was observed for 
reported pain and clinical size of lesions from the first 
day of treatment provided (Table I). Statistical analysis 
was performed only until T4. At T5 and T6 no patients 
presented lesions in the treated area. During the follow-
up period, at T7 only one patient developed a new lesion 
in the same treatment site; all patients continued to have 
other oral lesions at untreated sites.
All subjects were initially advised of the possible 
unpleasant taste of the medication, and 28% (2 patients) 
still reported this effect at the end of the follow-up period. 
No patient reported other adverse effects.
DISCUSSION 
This is the first reported study showing the effectiveness 
of CBPG and LLLT in reducing intraoral discomfort 
from ulcerations in patients with dystrophic EB, being 
effective also in the long-term.
Although the number of patients included in this pilot 
study is low, and EB is a rare condition, our results are 
promising because the oral lesions treated resolved in a 
short time with only one relapse within 24 weeks after 
the completion of therapy.
The oral mucosa in patients with EB can be affected 
with different lesions and degrees of severity, even if 
their patterns are still unclear (10).
It has been shown that CBPG releases high levels of 
vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF), suggesting that CBPG 
might be useful where high levels of VEGF and PDGF 
may be desirable (e.g. mucosal and skin lesions) (7).
Wound healing and tissue repair are complex pro-
cesses that involve different events (11); LLLT could 
effectively accelerate the healing of injured tissues, 
induce cell proliferation, and increase nucleic acid and 
collagen synthesis (12). We decided to add LLLT to the 
use of CPBG (remembering the objective difficulty of 
applying gel within the oral cavity) in order to possibly 
enhance its potential, by adding analgesic, regenerative 
and immunomodulatory effects (13). The basic principle 
of LLLT is based on its biomodulation effect: irradiation 
at a specific wavelength is able to alter cellular behaviour, 
obtaining different biological reactions to stimulate rege-
nerative abilities without adverse effects, and reducing 
the pharmacological support required (8).
Although this pilot study revealed that CPBG could be 
a safe and, possibly, a promising option for the treatment 
of EB oral lesions, defined randomized controlled trials 
are needed, to determine which of the 2 interventions 
could work better (alone or in combination).
The authors declare no conflicts of interest.
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Table I. Evaluation of selected data during the first 10 days of the offered protocol period
T1 (day 1) 
Mean ± SD
T2 (day 2) 
Mean ± SD
T3 (day 3) 
Mean ± SD
T4 (day 10) 
Mean ± SD T1 vs.T2b T1 vs.T3b T1 vs.T3b
Pain (VAS score)a 4.57 ± 3.24 2.81 ± 2.76) 1.51 ± 1.76) 0.47 ± 1.12 p = 0.003 p = 0.000 p = 0.000
Maximal width, mm 9.50 ± 4.82 8.25 ± 5.51 4.81 ± 6.50 0.25 ± 1.00 N/A N/A N/A
Maximal width, mm 8.69 ± 4.66 7.00 ± 3.98 3.25 ± 4.23 0.19 ± 0.75 N/A N/A N/A
Area, cm2 96.00 ± 75.76 75.06 ± 88.54 40.56 ± 77.39 0.75 ± 3.00 p = 0.007 p = 0.007 p = 0.001
aAfter the laser session. bTest statistics: Wilcoxon signed ranks test.
VAS: visual analgue scale; SD: standard deviation.
